Thermo Fisher Scientific teams up with Mindray

By staff writers

February 10, 2021 -- Thermo Fisher Scientific has partnered with Mindray to introduce two clinical chemistry analyzers for drug screening in clinical and drug court laboratories in the U.S. and Canada.

Thermo Fisher will offer Mindray's BS-480 and BA-800M analyzers to toxicology labs. BS-480 can provide 400 tests per hour, while BA-800M can perform 800 tests per hour, according to the vendors.

In addition, Thermo Fisher will provide a menu of its wet lab-validated dopamine reuptake inhibitor (DRI) and cloned enzyme donor immunoassay (CEDIA) drugs-of-abuse immunoassay reagents with the instruments, enabling urine samples to be screened for the presence of a given drug or class of drugs, the firm said.

Thermo Fisher to acquire Mesa Biotech for $450M
Thermo Fisher Scientific plans to acquire point-of-care molecular diagnostics provider Mesa Biotech for $450 million in cash.
6 trends to watch at AACC 2020
Although this year's meeting of the American Association for Clinical Chemistry (AACC) is virtual, it is probably more important than ever. Bruce Carlson...
Thermo Fisher's Q3 earnings boosted by COVID-19 sales
Products related to the novel coronavirus are spelling success for Thermo Fisher, which reported that revenue was up by 36% in the third quarter to $8.52 billion,...
Thermo Fisher debuts hematology/oncology assays
Thermo Fisher Scientific has debuted hematology/oncology assays that enable simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid...

Copyright © 2021

Last Updated ls 2/9/2021 6:05:41 PM